Genentech/Dako.
This article was originally published in The Gray Sheet
Executive Summary
Forge collaboration agreement under which Denmark firm Dako will develop an in vitro diagnostic breast cancer screening kit to detect over-expression of the HER2 growth factor receptor. Genentech is developing a humanized monoclonal antibody to HER2, Herceptin, for use as a possible breast cancer treatment. DAKO will gain rights to develop the immunohistochemical assay in return for royalties on worldwide sales...